This is a working overview of PPARδ agonist, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-07-18. Anything still debated is marked as such rather than presented as settled.
Laboratory detection of GW501516 commonly uses liquid chromatography coupled with tandem mass spectrometry. The method can identify the parent compound or its metabolites in urine and blood after sample cleanup. Protein precipitation, solid-phase extraction, or enzymatic hydrolysis may precede analysis, depending on the matrix. Reference standards are required for accurate quantification and confirmation. Because the compound is not approved, testing often occurs in anti-doping, forensic, or research settings rather than routine clinical care. Results are reported with limits of detection and quantification.
Stability of GW501516 depends on form, temperature, light exposure, and moisture. Solid reference material is typically stored frozen or refrigerated in a desiccator and protected from light. Solutions in organic solvents such as dimethyl sulfoxide are often kept frozen in aliquots to reduce freeze-thaw cycling. Aqueous solubility is low, so aqueous stock solutions can be difficult to prepare without cosolvents. Degradation may appear as changes in chromatographic purity or mass spectral signal. Stability studies are needed to establish shelf life for any specific preparation.
Laboratory studies indicate that GW501516 activates PPARδ, a nuclear receptor involved in fatty acid oxidation and energy metabolism. In rodent experiments, treated animals often showed increased endurance and reduced fat mass. These effects were observed under controlled conditions and do not establish safe or effective use in humans. The exact dose-response relationship in humans remains poorly characterized. Species differences in metabolism can affect how results translate across animals and people.
Safety concerns emerged from long-term animal studies. In rodents given the compound for extended periods, researchers found an increased incidence of certain cancers, including liver and bladder tumors. These findings contributed to the discontinuation of clinical development. Whether similar risks apply to short-term or low-level exposure in humans is not established, and controlled human safety data are limited. The relevance of high-dose rodent carcinogenicity findings to human use remains a subject of debate.
Human trials of GW501516 were small and short in duration. They examined lipid levels, glucose handling, and other metabolic markers, but the programs were halted after the animal cancer findings. No approved therapeutic product exists, and published human data are insufficient for establishing long-term safety. Reports of use for athletic performance come mainly from non-clinical settings and cannot be verified through controlled trials. Independent testing of products sold as cardarine has found inconsistent purity and labeling.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Common for reference-grade material. |
| Solubility | Low in water | Dissolves in DMSO and some organic solvents. |
| Typical storage | -20 °C, desiccated | Protect from light and moisture. |
| Analytical method | LC-MS/MS | Used for trace detection in biological matrices. |
| Purity assessment | HPLC with UV detection | Often combined with NMR and mass spectrometry. |
Regulatory treatment varies, but cardarine is not approved as a medicine. Sports authorities list GW501516 as a prohibited substance, and it is banned at all times under the World Anti-Doping Agency code. Many countries restrict sales for human consumption, while online vendors market it as a research chemical. Such products may lack purity data, and their actual contents can differ from the label. Purchasing or possessing cardarine may carry legal consequences depending on jurisdiction. The compound is not a dietary supplement ingredient in regulated markets.
Clinical development stopped after rodent studies showed tumors at multiple sites. Whether those findings predict human cancer risk remains an open question, but they led sponsors to discontinue programs. Human safety data are limited to small, short-term studies that were not designed to assess cancer risk. Reported effects in those studies included changes in blood lipids, but the evidence is insufficient for medical use. Long-term consequences of nonmedical use are not well characterized. Questions about dose, duration, and individual susceptibility remain unresolved.
Cardarine is not approved for human therapeutic use in any major jurisdiction. It appears on the World Anti-Doping Agency Prohibited List as a PPARδ agonist within the hormone and metabolic modulators category. Sports organizations test for it because it has been detected in athlete samples and seized products. Regulatory actions against marketed research chemical versions have occurred in several countries, though enforcement varies. Availability through unregulated channels complicates oversight.
Analytical laboratories typically identify cardarine and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is a common matrix in anti-doping testing, while blood and tissue may be used in research settings. Detection windows depend on the assay, the sample matrix, and the compound's metabolism. Because cardarine is extensively metabolized, laboratories often target specific metabolites to improve sensitivity and confirmation. Reference standards are required for reliable quantification. Method validation includes checks for selectivity, linearity, and carryover.
A persistent misconception is that cardarine is a fat-burning drug or a safe alternative to anabolic steroids. No approved therapeutic product exists, and human safety data are limited. The tumor findings in rodents remain a central concern in scientific reviews. Products sold online may contain inaccurate labels, impurities, or different compounds entirely, which complicates any assessment of effects. Independent testing of such products has reported frequent mislabeling. For these reasons, discussions in the literature emphasize risks and unknowns rather than benefits.
Cardarine can be detected in biological samples and product materials using liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS). The method separates compounds by chromatography and identifies them by mass-to-charge transitions, allowing low-level detection in urine or blood. Sample preparation often involves enzymatic hydrolysis, solid-phase extraction, or protein precipitation. Certified reference materials and isotope-labeled internal standards improve quantification. Detection windows depend on metabolism, matrix, and assay sensitivity, so no single universal window applies.
Regulatory treatment of cardarine differs by context and jurisdiction. In competitive sport, the World Anti-Doping Agency lists PPARδ agonists, including GW501516, as prohibited at all times. Outside sport, it lacks approval as a prescription medicine in major drug markets, and products sold for human consumption may be treated as unapproved drugs. Some countries also restrict importation or sale through general consumer protection and medicines laws. These classifications affect availability, testing, and legal risk without establishing therapeutic value.
Because cardarine is not an approved medicine, no pharmacopeial monograph defines its identity, purity, or storage requirements. Laboratories typically rely on in-house methods and reference standards when testing materials labeled as GW501516. Certificates of analysis may report purity and identity for a specific batch, but their scope varies and they do not guarantee safety or legal status. Independent verification can include high-performance liquid chromatography, mass spectrometry, nuclear magnetic resonance, and elemental analysis. The distinction between research chemical labeling and human use is significant because quality standards and oversight differ.
The declaration had two indirect consequences, the emergence of Israel and a chronic state of conflict between Arabs and Jews throughout the Middle East. It has been described as the "original sin" with respect to both Britain's failure in Palestine and for wider events in Palestine. The statement also had a significant impact on the traditional anti-Zionism of religious Jews, some of whom saw it as divine providence; this contributed to the growth of religious Zionism amid the larger Zionist movement. Starting in 1920, intercommunal conflict in Mandatory Palestine broke out, which widened into the regional Arab–Israeli conflict, often referred to as the world's "most intractable conflict". The "dual obligation" to the two communities quickly proved to be untenable; the British subsequently concluded that it was impossible for them to pacify the two communities in Palestine by using different messages for different audiences. The Palestine Royal Commission – in making the first official proposal for partition of the region – referred to the requirements as "contradictory obligations", and that the "disease is so deep-rooted that, in our firm conviction, the only hope of a cure lies in a surgical operation". Following the 1936–1939 Arab revolt in Palestine, and as worldwide tensions rose in the buildup to the Second World War, the British Parliament approved the White Paper of 1939 – their last formal statement of governing policy in Mandatory Palestine – declaring that Palestine should not become a Jewish State and placing restrictions on Jewish immigration.
Tui na (推拿) is a form of massage, based on the assumptions of TCM, from which shiatsu is thought to have evolved. Techniques employed may include thumb presses, rubbing, percussion, and assisted stretching.
During the Macedonian dynasty, efforts to reform law began with the publication of the Procheiron and the Eisagoge, which aimed to define the emperor's power under prevailing laws, and to replace the Ekloge due to its association with iconoclasm. Leo VI (r. 886–912) completed a complete codification of Roman law in Greek through the Basilika, a work of 60 books which became the foundation of Byzantine law. In 1345, Constantine Harmenopoulos compiled the Hexabiblos, a six-volume law book derived from various Byzantine legal sources.
Sources: en.wikipedia.org
The Racial Discrimination Act 1975 created the first general right against race discrimination. However, in 2019 the median adjusted weekly household income for Indigenous Australians over 15 was just $623 compared to $935 for non-Indigenous residents, a 33.3% race pay gap. In 2016, the census showed a gap of 72% employment for non-Indigenous Australians to just 47% employment rate for Indigenous Australians. There have not yet been institutions to set aside a portion of the funds from Australia's natural resources for Indigenous Australian well-being, nor are there yet clear principles established to ensure that historic disadvantage is undone, as in South Africa, India, or Europe, through positive action.
=== Restoration === The role of ectomycorrhizas in supporting their host plants has led to the suggestion that EcM fungi could be used in restoration projects aimed at re-establishing native plant species in ecosystems disrupted by a variety of issues. Since the disappearance of mycorhizal fungi from a habitat constitutes a major soil disturbance event, their re-addition is an important part of establishing vegetation and restoring habitats.
=== Plot === Blue Shift begins similarly to Half-Life, as Barney Calhoun rides a train through the Black Mesa research facility to reach his place of work. After reporting for duty, Calhoun is instructed to assist in maintenance on a malfunctioning elevator. As Calhoun finishes repairs, however, Freeman's experiment takes place and results in a "resonance cascade", causing massive damage to the facility and teleporting alien creatures into the base. The elevator is badly damaged and fails, sending Calhoun plummeting into the depths of Black Mesa. Calhoun regains consciousness at the bottom of the shaft and begins to fight his way to the surface to escape. Emerging near Black Mesa's classification yards, Calhoun learns that Dr. Rosenberg and his colleagues plan to escape the facility using teleportation technology. After freeing Rosenberg from the captivity of the US Marines detachment sent to silence the facility, Calhoun escorts him to a decommissioned prototype teleportation laboratory, where several Black Mesa employees have already gathered. Rosenberg then teleports Calhoun to the Xen borderworld to calibrate research equipment needed to pinpoint a teleport destination outside of Black Mesa. Upon his return, Rosenberg informs Calhoun that the teleporter's battery power has been exhausted, and contact has been lost with a team sent to acquire a new power cell. Calhoun travels to the power generators on a lower level to find a fresh power cell while firefights rage between the Marines and the forces of Xen.
== External links == "Ghrelin Receptor". IUPHAR Database of Receptors and Ion Channels. International Union of Basic and Clinical Pharmacology. Archived from the original on 2015-07-11. Retrieved 2007-10-25. growth+hormone+secretagogue+receptor at the U.S. National Library of Medicine Medical Subject Headings (MeSH) Ghrelin Archived 2008-05-12 at the Wayback Machine at Colorado State University This article incorporates text from the United States National Library of Medicine, which is in the public domain.
Sources: en.wikipedia.org
LC-MS/MS is common, often after sample cleanup. The assay targets GW501516 or its metabolites.
Reference material is usually kept cold, dry, and protected from light. Frozen aliquots reduce repeated freeze-thaw cycles.
No approved pharmaceutical product exists, so manufacturing and quality controls are not standardized. Products may contain different compounds or impurities.
Rodent studies reported increased endurance and fat oxidation after GW501516 exposure. Long-term studies also found higher rates of some tumors, which led to halted development.